Innovimmune's Preclinical Data on Highly Selective ROR Gamma Inhibitor Prevents Multiple Sclerosis in Mice Print
By GLOBE NEWSWIRE   
Wednesday, 15 January 2014 02:35

NEW YORK--Specialty drug discovery company, Innovimmune Biotherapeutics Holding, LLC presented data at the XXI World Congress of Neurology in Vienna, Austria (September 22-24, 2013) that demonstrated robust efficacy in preventing multiple sclerosis [MS] in a preclinical mouse model following treatment with its proprietary oral small molecule Retinoic acid receptor-related Orphan Receptor ROR gamma (t) [ROR gamma t] modulators from their INV-17 portfolio.

The abstract titled "EAE Disease Prevention by a Potent Oral ROR gamma t Inverse Agonist INV-17: A Promising Safe & Efficacious MS Treatment" showed that MS was successfully prevented and the compound was well tolerated in INV-17-treated mice: http://www.jns-journal.com/article/S0022-510X(13)01638-9/abstract. Prophylactic INV-17 treatment prevented disease development in the murine experimental autoimmune encephalomyelitis [EAE] model. The superior therapeutic efficacy of INV-17 demonstrated significantly lower clinical scores with minimal cumulative EAE (3.3 ± 3.3; p < 0.01) and clinical area under the curve [AUC] scores (3.00 ± 3.00; p < 0.01), in striking contrast to control vehicle-treated mice, all of which developed severe EAE (27.9 ± 6.2) and high clinical AUC scores (26.50 ± 6.28).

"This is a remarkable finding in that a novel therapeutic approach targeting pathogenic T helper 17 [TH17] cells provides superior preclinical efficacy. These results, which demonstrate disease prevention in the absence of toxicity, may provide a novel disease-modifying treatment strategy with an oral INV-17 drug to patients with MS and other TH17-mediated autoimmune diseases," said Daniel M. Rosenbaum, MD; Professor of Medicine and Chair, Department of Neurology, SUNY Downstate Medical Center.

ROR gamma t is the master regulator of human TH17 cells that play a critical role in the pathogenesis of several autoimmune diseases. The development of INV-17 clinical lead compounds is being fast-tracked concurrently for potential therapeutic applications in multiple ROR gamma t-regulated autoimmune diseases with significant unmet medical need.

"We believe our best-in-class ROR gamma t inhibitors will provide significant treatment advancement in several autoimmune disease indications. Establishing our first preclinical Proof of Concept in MS is an important development milestone for the INV-17 program. Such early therapeutic promise in preclinical MS supports the fast-tracked development and therapeutic utility of INV-17, not only in MS, but also for other autoimmune diseases," said Anderson Gaweco, MD, PhD, CEO of Innovimmune.

ABOUT INNOVIMMUNE

Innovimmune Biotherapeutics Holding, LLC is a New York City-based specialty drug discovery and exploratory development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule New Molecular Entity immunomodulatory drugs for the treatment of autoimmune and immunoinflammatory diseases.

CONTACT: Corporate Inquiries:				          Anderson Gaweco					          Innovimmune Biotherapeutics Holding, LLC          +1 (718) 282 2814					          media@innovimmune.com				           Media Inquiries:           Jules Abraham          JQA Partners, LLC          +1 (917) 885 7378          jabraham@jqapartners.com



BiomedReports is not paid or compensated by newswires to disseminate or report news and
developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and

Error. Page cannot be displayed. Please contact your service provider for more details. (7)

investor relation services from various entities and
firms. Full disclosures should be read in the 'About Us Section'.


Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1